Newsroom
July 30, 2021
Dr. Gabriel A. de Erausquin, Neurology/Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, had his team’s study reported in the Washington Post. The study, conducted in Argentina, found that adults over the age of 60 were likely to have issues with cognitive function, such as memory loss and confusion, after a COVID-19. Read story
July 30, 2021
Dr. Gabriel A. de Erausquin, Neurology/Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, had his team’s study reported in Forbes. The study, conducted in Argentina, found that adults over the age of 60 were likely to have issues with cognitive function, such as memory loss and confusion, after a COVID-19 infection. Read story
July 29, 2021
Loss of smell also observed in Argentine sample. Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu DENVER, Colo. (July 29, 2021) — In a sample of over 400 older adults in Argentina who had recovered from COVID-19, more than 60% displayed some degree of cognitive impairment, a researcher from The University of Texas Health Science Center at San […]
July 27, 2021
Dr. Gabriel de Erausquin and Dr. Sudha Seshadri, Neurology/Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, and Dr. Monica Verduzco-Gutierrez, Rehabilitation Medicine, are quoted in this NPR story and share their research findings of how COVID-19 affects the brain. Listen here
June 17, 2021
Middle-aged people with depressive symptoms who carry a genetic variation called apolipoprotein (APOE) ε4 may be more at risk to develop tau protein accumulations in the brain’s emotion- and memory-controlling regions, a new study by researchers from UT Health San Antonio and collaborating institutions suggests.
May 7, 2021
Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for treating neurodegenerative brain injuries, is mentioned in this MedCity News story. Dr. James Lechleiter, Cell Systems and Anatomy, is the inventor and patent holder on technology licensed to Astrocyte Pharmaceuticals Inc. Read the story.